We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Molecular Methods Differentiate Breast Cancers

By LabMedica International staff writers
Posted on 01 May 2012
Molecular technology has been used to the reclassify the manifestations of breast cancer into a multiplicity of different diseases. More...


By analyzing the DNA and ribonucleic acid (RNA) from breast cancer tumors, it is proposed that what are called breast cancer are in fact at least 10 different diseases, each with its own molecular fingerprint and pattern of weak spots.

In a landmark study that promises to revolutionize diagnosis and prognosis, and pave the way for individualized, tailored treatment, British and Canadian scientists uncovered crucial new information about breast cancer. The scientists analyzed the DNA and RNA of breast tumor samples from nearly 2,000 women who had been diagnosed between 5 and 10 years ago, and for whom information about the tumor characteristics had been meticulously recorded. The teams were from the Cambridge Research Institute (UK) and British Columbia Cancer Center (Vancouver, BC, Canada).

The team performed analyses on the DNA of the tumors--for instance, the map is now annotated with copy number changes and single letter variations or single-nucleotide polymorphism, for each tumor. The scientists also conducted a detailed analysis of the tumor RNA so they can tell which genes were active in each sample. Altogether, they did this for more than 30,000 types of RNA, each corresponding to the activity of a single gene.

The study revealed the relationship between breast cancer genes and known signaling pathways, the networks that control cell growth and division. This invaluable knowledge will help identify how variants of these genes cause cancer by interfering with cell processes. The team also discovered several previously unknown genes that drive breast cancer. Each of these is a potential target for new drugs, and should boost worldwide efforts to discover and develop new treatments.

Carlos Caldas, MD, professor of Cancer Medicine at Cambridge said, "We've drilled down into the fundamental detail of the biological causes of breast cancer, and we've moved from knowing what a breast tumor looks like under a microscope to pinpointing its molecular anatomy. Our results will pave the way for doctors in the future to diagnose the type of breast cancer a woman has, the types of drugs that will work, and those that won't, in a much more precise way than is currently possible." The study was published in the April 18, 2012, online issue of Nature.

Related Links:
Cambridge Research Institute
British Columbia Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.